New Real-World Data Show Benefits Of Abbott's FreeStyle Libre Technology
New real-world data, presented at a recent diabetes conference in Madrid, showed that Abbott's FreeStyle Libre system provided several clinical benefits for patients with diabetes.
You may also be interested in...
Abbott has signed a partnership with Insulet Corporation to create an integrated technology that automatically adjusts insulin delivery based on personalized glucose data.
Market Brief: Abbott, Dexcom Help Drive Continuous Glucose Monitoring Market; 30% Expected Growth by 2023
Global sales of blood glucose monitoring devices are expected to reach $13bn by 2023, a CAGR of nearly 11%, led by the rising adoption of continuous glucose monitoring systems (CGMs). Abbott and Dexcom have been major drivers in the CGM market, but competition is fierce.
In this edition of the Device Week podcast, Medtech Insight managing editor Marion Webb discusses LifeSignals’ plans for a vital-sign monitoring patch that could help remotely monitor patients during the pandemic. Deputy editor Reed Miller highlights some important device trials presented at the American College of Cardiology online conference.